SCHEMBL23792019

SCHEMBL23792019

CC(C)Cc1sc(NCC(NC(=O)OC(C)C)C(=O)O)nc1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRN P28799 1/20 0.38
▸ SORT1 Q99523 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ PTGDR2 Q9Y5Y4 3/20 0.36
▸ HTT P42858 1/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ FBP1 P09467 2/20 0.34
▸ BRAF P15056 3/20 0.33
▸ PDE4A P27815 2/20 0.33
▸ PDE4B Q07343 2/20 0.33
▸ PDE4C Q08493 2/20 0.33
▸ PDE4D Q08499 2/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23791724 0.90 DHODH (0.42) GRNSORT1LMNANPC1POLB
SCHEMBL23782338 0.90 ACE (0.37) GRNSORT1LMNANPC1POLB
SCHEMBL26240299 0.89 GRN (0.40) GRNSORT1LMNANPC1POLB
SCHEMBL23792015 0.88 GRN (0.40) GRNSORT1LMNANPC1POLB
SCHEMBL23782502 0.87 CTSK (0.42) PTGDR2DHODH
SCHEMBL30173796 0.86 GRN (0.47) GRNSORT1LMNANPC1POLB
SCHEMBL23782529 0.86 GRN (0.47) GRNSORT1LMNANPC1POLB
SCHEMBL23792000 0.85 FPR2 (0.45) GRNSORT1LMNANPC1POLB
SCHEMBL23792013 0.84 GRN (0.41) GRNSORT1LMNANPC1POLB
SCHEMBL23792017 0.83 MEN1 (0.41) GRNSORT1LMNANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 GRN 1587/4885SORT1 4202/4885LMNA 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback